scispace - formally typeset
J

Jerry W. Simecka

Researcher at University of North Texas Health Science Center

Publications -  95
Citations -  3785

Jerry W. Simecka is an academic researcher from University of North Texas Health Science Center. The author has contributed to research in topics: Mycoplasma pulmonis & Immune system. The author has an hindex of 35, co-authored 95 publications receiving 3578 citations. Previous affiliations of Jerry W. Simecka include University of Alabama & University of North Texas System.

Papers
More filters
Journal ArticleDOI

Biofilm Formation and Dispersal under the Influence of the Global Regulator CsrA of Escherichia coli

TL;DR: It is established that the RNA binding global regulatory protein CsrA (carbon storage regulator) of Escherichia coli K-12 serves as both a repressor of biofilm formation and an activator ofBiofilm dispersal under a variety of culture conditions.
Journal ArticleDOI

Positive regulation of motility and flhDC expression by the RNA-binding protein CsrA of Escherichia coli

TL;DR: It is shown that the global regulator CsrA of E. coli K‐12 is necessary for motility under a variety of growth conditions, as a result of its role as an activator of flhDC expression.
Journal ArticleDOI

Catabolite repression of Escherichia coli biofilm formation.

TL;DR: A temporal role for cAMP in biofilm development was indicated by the finding that glucose addition after approximately 24 h failed to repress and generally activated biofilm formation.
Journal ArticleDOI

Intratracheal Gene Delivery with Adenoviral Vector Induces Elevated Systemic IgG and Mucosal IgA Antibodies to Adenovirus and β-Galactosidase

TL;DR: Evidence suggests that the lung and associated lymphoid tissues were the source for serum antibodies, and that the highest IgA spot-forming cell (SFC) response to Ade5 and beta-Gal was located in the NP and in the lung.
Journal ArticleDOI

Roles of Innate and Adaptive Immunity in Respiratory Mycoplasmosis

TL;DR: It is found that numbers of mycoplasmas in lungs were associated with genetic background (C3H susceptible, C57BL resistant) rather than functional state of adaptive immunity, indicating that innate immunity is the main contributor to antimyCoplasmal defense of the lungs.